Table 15.

Features of the enzymes drugs approved by the Food and Drug Administration (FDA) from 2011 to 2021. The order of drugs is tabulated in order of most recent to oldest registration date.

No.	Generic Name of Drug	Brand Name and Company	First FDA/EMA Approved Date	Class	Molecular Target	Route of Administration	Indication	Adverse Effects	Reference
1	Calaspargase pegol-mknl	ASPARLAS Servier Pharmaceuticals, Boston, MA, USA	FDA: 20 December 2018 EMA: Not approved	Asparagine-specific enzyme	Asparagine level	Intravenous	Acute Lymphoblastic Leukemia	Elevated transaminase, bilirubin increased, pancreatitis, abnormal clotting studies	[280]
2	Asparaginase Erwinia chrysanthemi	ERWINAZE Jazz Pharmaceuticals plc, Dublin, Ireland	FDA: 18 November 2011 EMA: nationally authorized	Asparagine-specific enzyme	Asparagine level	Intravenous	Acute Lymphoblastic Leukemia	Anaphylaxis, pancreatitis, abnormal transaminases, thrombosis, hemorrhage, nausea, vomiting, hyperglycemia.	[283,284,285]